Results 161 to 170 of about 1,783,713 (249)

Kikuyu grass clippings as a bioeconomy feedstock: influence of pyrolysis conditions on biochar properties and its effect on the growth of Swiss chard

Biofuels, Bioproducts and Biorefining, EarlyView.
Abstract The integration of urban organic waste streams into the bioeconomy is critical for advancing the water–food–energy nexus. Grass clippings, an abundant and underutilized municipal residue, represent a promising feedstock for producing value‐added materials.
Ami Janse van Rensburg, Herman Potgieter, Yusuf Makarfi Isa   +2 more
wiley   +1 more source

Leveling the start: cost-effectiveness of community-based doula care among Medicaid births^∗. [PDF]

BMC Public Health
Malak N.
europepmc   +1 more source

Financial Crisis Inquiry Commission

, 2011
This website contains the research and final report for the Financial Crisis Inquiry Commission looking at the causes of the economic ...
United States. Financial Crisis Inquiry Commission.
core  

Optimization of pharmaceutical research and development by early‐phase assessment of investigational medicinal products

British Journal of Clinical Pharmacology, EarlyView.
Small and mid‐sized pharmaceutical innovators often have limited in‐house health economics and market access expertise, and may struggle to align development strategies of investigational medicinal products with health system needs and payer expectations.
Zoltán Kaló, Attila Imre, Gábor Varga, Sándor Kovács, György Tímár, Balázs Nagy   +5 more
wiley   +1 more source

The Reverse Risk Register Approach to Understanding Systemic Factors in Risk Analysis and Management Case Studies. [PDF]

Risk Anal
Thekdi S, Aven T.
europepmc   +1 more source

Early‐stage health technology assessment of a curative gene therapy for multiple sclerosis

British Journal of Clinical Pharmacology, EarlyView.
Aims Multiple sclerosis (MS) is associated with significant early morbidity, reduced life expectancy and substantial healthcare and societal costs. The primary objective of this study is to assess the early cost‐effectiveness potential of a novel gene therapy, IMMUTOL, for MS compared with current high‐efficacy treatment sequences.
Attila Imre, Balázs Nagy, Rok Hren
wiley   +1 more source

Multivariate analysis of poverty and social exclusion across EU countries in the context of Sustainable Development Goal 1. [PDF]

PLoS One
Megyesiova S, Olexova C.
europepmc   +1 more source

Cost‐utility analysis of nusinersen–risdiplam switch in patients with spinal muscular atrophy in Croatia: A discrete event simulation model

British Journal of Clinical Pharmacology, EarlyView.
Introduction In recent years, the treatment of spinal muscular atrophy (SMA), a rare disease, has significantly progressed, improving patients' survival and overall quality of life. However, current SMA treatments are expensive, and some (nusinersen) are very inconvenient for patients.
Andrej Belančić, Ivana Stević, Elvira Meni Maria Gkrinia, Dinko Vitezić, Slobodan Janković   +4 more
wiley   +1 more source

Analysis of Financial Crowding Out in the Iraqi Economy for the Period 2004 - 2022. [PDF]

F1000Res
Jabbar A, Dikheel B.
europepmc   +1 more source

Beyond the label: Rethinking off‐label drug use in paediatrics. Towards a scientifically grounded and safer future for paediatric pharmacotherapy

British Journal of Clinical Pharmacology, EarlyView.
Abstract Despite regulatory progress being made in the past two decades, off‐label drug use in paediatrics remains pervasive, with prevalence estimated between 3% and 97% of prescriptions across different clinical settings. Off‐label use—defined as prescribing outside the conditions described in the Summary of Product Characteristics (SmPC)—is often ...
Tjitske M. van der Zanden, Miriam G. Mooij, Matthijs de Hoog, Saskia N. de Wildt   +3 more
wiley   +1 more source